Cambridge-based CN Bio, an organ-on-a-chip company that designs and manufactures single-and multi-organ microphysiological systems, has appointed Joseph Parisi as US director of sales to lead the expansion of the company’s sales and support activities for the US market and address demand for new alternative methodologies in preclinical drug discovery.

Parisi has experience of sales in the biotechnology sector. He was previously director of sales for US West at Phenomix (acquired by Bruker Corporation last year), responsible for growing the proteomics side of the business. Before that, he was director of West Coast sales at Purigen Biosystems (acquired by Bionano Genomics in 2022). He has also worked in senior roles at numerous life sciences organisations, including Isoplexis, NanoString Technologies, and Life Technologies.

Parisi said: “The potential offered by CN Bio’s PhysioMimix range, substantiated by the company’s collaborative work with the FDA, is truly transformative for the drug discovery industry, providing clinical translatability that can improve efficiency and minimise drug failures. In my new role, I look forward to harnessing my experience within the sector to support the design and implementation of a commercial strategy that will enable us to meet the significant demand for animal model alternatives here in the US.”

CN Bio’s chief executive Dr Paul Brooks commented: “Throughout his career [Parisi] has repeatedly demonstrated his expertise in biotech sales, with a proven history of success across companies at all stages of growth and commercialisation. Joe’s appointment represents an important milestone in CN Bio’s growth, having successfully built a strong international presence and now looking to expand this further into the US, a key market for innovative drug discovery.”